Citations

Clear

16280 citation(s) found for "Yu, David".

Combined TaTME with SP Robot for Low Anterior Resection in Rectal Cancer: rSPa TaTME
Keshk, Nouran O., Perez-Pachon, Mauricio E., Gomaa, Ibrahim A. , Aboelmaaty, Sara , Rumer, Kristen K. , Shawki, Sherief , Gomaa, Ibrahim , Keshk, Nouran O., Larson, David W.

Mayo Clinic

Cancers | April 15, 2025 | Volume: 17 | Issue: 8 | Pages: 1328

10.3390/cancers17081328 | PMID 40282504 Get It

Background: Total mesorectal excision (TME) remains the gold standard for the resection of rectal cancer regardless of the modality: open, laparoscopic, or robotic. The transanal TME (TaTME) approach has been utilized to overcome the difficulties encountered with the dissection of tumors in the distal pelvis. Recently, a single-port robotic approach (rSPa) was introduced, where three arms and a camera emanate from a 2.5 cm diameter port. This report presents the first experience in the United States combining those two approaches (rSPa TaTME) in rectal cancer, evaluating its safety and oncologic outcomes. Methods: This is a retrospective review of our prospectively maintained rectal cancer database. Patient demographics, tumor characteristics, neoadjuvant treatment, and oncologic and surgical outcomes were recorded. Results: Between May 2022 and August 2024, ten patients (six females, four males) with a median age at surgery of 53 years (range: 38–85) and a mean BMI of 26 (±5) kg/m2 were included for analysis. The median distance of tumors from the anorectal junction was 3.2 cm (range: 2–5.3 cm). All patients had negative margins, with eight complete TME specimens, one near complete, and one incomplete. The mean number of lymph nodes harvested was 24 (±11). The average operative time was 351 (243–411) min. The average length of stay was four days. The ileostomy was reversed in nine out of ten patients. Six patients experienced complications within 30 days of surgery. There were no local or distal recurrences, with a mean follow-up of 20 months (range: 4–30). Conclusions: rSPa TaTME is a unique and innovative method of combining two minimally advanced approaches for the resection of distal rectal cancers, with acceptable surgical and oncologic outcomes.
Practice Standards for Acute Hospital Care at Home
Levine, David M. , DeCherrie, Linda V. , Siu, Albert L. , Schiller, Gabrielle , Timpe, Chrisanne , Murphy, Stephanie , Lung, C. P., Nottidge, Michael, Titchener, Karen , Paulson, Margaret, Paulson, Margaret R. , Leff, Bruce A.

Mayo Clinic

Journal of the American Geriatrics Society | April 15, 2025 | Volume: 73 | Issue: 7 | Pages: 2037-2045

10.1111/jgs.19427 | PMID 40156507 Get It

ABSTRACT Background Hospital at home (HaH) provides hospital‐level care at home as a substitute for brick‐and‐mortar hospital care. Multiple HaH studies demonstrate HaH provides safe, high‐quality, cost‐effective care. However, practices have varied approaches to delivering care and no HaH‐specific national standards exist. We aimed to develop national practice standards for HaH and assess practice performance against the standards. Methods The HaH Users Group (HaHUG), the national convener of HaH practices, assembled the Practice Standards Council in 2019 to develop evidence‐based standards for HaH. We reviewed existing international standards and the requirements of the Centers for Medicare and Medicaid Services Acute Hospital Care at Home Waiver. We engaged in multiple iterative rounds to develop domains and standards within each domain and then held an open comment period. We distributed an online survey for all HaHUG practices to self‐assess whether they did not meet (score, −1), met (score, 0), or exceeded (score, +1) each standard. The American Hospital Association's Annual Survey was used to describe practices that did and did not complete the practice standards survey. Results Final practice standards included 31 standards in 7 domains: leadership; education and training; human resources management; quality and quality improvement; safe practice and environment; and clinical standards and protocols. The majority of HaH practices self‐rated that they met or exceeded standards: scores ranged from −5 to 31; mean score of 9.75 (SD, 12.60). Forty‐nine of 213 eligible HaH practices completed the survey (response rate, 23.0%). Most hospitals were large (65% > 299 beds), nonprofit (85%), teaching (90%) centers that cared for a large proportion of patients with Medicaid. Conclusion We present the first national practice standards for HaH. The vast majority of HaH practices met or exceeded these standards by their own assessment. There was a range of performance across standards, demonstrating strengths and opportunities for ongoing development and quality improvement.
Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol
Reitinger, Jeremy C. , Reed, David M. , Peres, Cameron , Fan, Shan , Gulati, Vikas , Kazemi, Arash , Sit, Arthur J. , Moroi, Sayoko E. , Toris, Carol B. , Moroi, Sayoko E , Sit, Arthur J

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | April 14, 2025 | Volume: 41 | Issue: 5 | Pages: 251-258

10.1089/jop.2024.0112 | PMID 40229142 Get It

Purpose: To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. Methods: In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. Results: More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff ( p < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs ( p < 0.01). Among timolol nonresponders ( n = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders ( n = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. Conclusions: Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.
Clinical significance of sleepiness: an American Academy of Sleep Medicine position statement
Heffron, Thomas M., Gurubhagavatula, Indira , Trotti, Lynn Marie , Abbasi-Feinberg, Fariha, Abreu, Alexandre Rocha, Bandyopadhyay, Anuja , Kuhlmann, David, Olson, Eric J. , Shelgikar, Anita V., Rowley, James A. , Trotti, Lynn Marie , Kapur, Vishesh K. , Martin, Jennifer L , Patil, Susheel P. , Wickwire, Emerson M.

Mayo Clinic

Journal of Clinical Sleep Medicine | April 14, 2025 | Volume: 21 | Issue: 6 | Pages: 1103-1107

10.5664/jcsm.11658 | PMID 40078104 Get It

GLIM consensus approach to diagnosis of malnutrition: A 5‐year update
Jensen, Gordon L. , Cederholm, Tommy , Correia, María Isabel Toulson Davisson , González, Marı́a Cristina , Fukushima, Ryoji , Pisprasert, Veeradej , Cárdenas, Diana , Carrasco, Fernando , Cruz‐Jentoft, Alfonso J. , Cuerda, Cristina , Evans, David C. , Hasse, Jeanette M. , Hiki, Naoki, Jahit, Mohammad Shukri , Jáquez, Anayanet , Muscaritoli, Maurizio , Ng, Doris Hui Lan , Nyulasi, Ibolya , Pirlich, Matthias , Siltharm, S., Yu, Jianchun , Gossum, A. Van , Winkler, Marion F. , Compher, Charlene , Barazzoni, Rocco , Gautier, Juan B Ochoa , Gonzalez, M Cristina , Blaauw, Renee , Braz, Diana Cardenas , Carrasco, Fernando , Evans, David C , Fuchs-Tarlovsky, Vanessa , Gramlich, Leah , Hasse, Jeanette M , Hiesmayr, Michael , Jager-Wittenaar, Harriët , Jahit, Shukri , Jáquez, Anayanet , Keller, Heather , Malone, Ainsley , Mogensen, Kris M , Mundi, Manpreet S , Muscaritoli, Maurizio , Ng, Doris , Nyulasi, Ibolya , Schneider, Stephane , de van der Schueren, Marian , Singer, Pierre , Tappenden, Kelly A , Yu, Jianchun , Wang, Jaw-Yuan , Winkler, Marion F , Compher, Charlene , Gramlich, Leah , Shi, Han Ping , Kłęk, Stanisław , Malone, Ainsley , Mogensen, Kris M. , Mori, Naoharu , Mundi, Manpreet S. , Steiber, Alison

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | April 14, 2025 | Volume: 49 | Issue: 4 | Pages: 414-427

10.1002/jpen.2756 | PMID 40223699 Get It

Abstract Background The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 that comprised screening followed by assessment of three phenotypic criteria (weight loss, low body mass index [BMI], and low muscle mass) and two etiologic criteria (reduced food intake/assimilation and inflammation/disease burden). This planned update reconsiders the GLIM framework based on published knowledge and experience over the past 5 years. Methods A working group ( n = 43 members) conducted a literature search spanning 2019–2024 using the keywords “Global Leadership Initiative on Malnutrition or GLIM.” Prior GLIM guidance activities for using the criteria on muscle mass and inflammation were reviewed. Successive rounds of revision and review were used to achieve consensus. Results More than 400 scientific reports were published in peer‐reviewed journals, forming the basis of 10 systematic reviews, some including meta‐analyses of GLIM validity that indicate strong construct and predictive validity. Limitations and future priorities are discussed. Working group findings suggest that assessment of low muscle mass should be guided by experience and available technological resources. Clinical judgment may suffice to evaluate the inflammation/disease burden etiologic criterion. No revisions of the weight loss, low BMI, or reduced food intake/assimilation criteria are suggested. After two rounds of review and revision, the working group secured 100% agreement with the conclusions reported in the 5‐year update. Conclusion Ongoing initiatives target priorities that include malnutrition risk screening procedures, GLIM adaptation to the intensive care setting, assessment in support of the reduced food intake/assimilation criterion, and determination of malnutrition in obesity.
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer
Bachelot, Thomas , Sammons, Sarah , Shen, Sherry , Twelves, Chris, Boruta, Gina, Portman, David, Sammons, Sarah L , Goetz, Matthew P. , Wander, Seth Andrew , Nonneville, Alexandre Tassin de , Gal‐Yam, Einav Nili , Damodaran, Senthil

Mayo Clinic

Future Oncology | April 13, 2025 | Volume: 21 | Issue: 11 | Pages: 1317-1324

10.1080/14796694.2025.2481825 | PMID 40222048 Get It

Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 US rheumatology clinics
Singh, Jasvinder A. , Eisen, Seth A. , Chatham, Winn, Narain, Sonali , Kamen, Diane L. , Trotter, Kimberly , Majithia, Vikas , Ching, Cathy Lee , Aouhab, Zineb , Venuturupalli, Swamy, McMahon, Maureen , Bhairavarasu, Kalpana, Beasley, Mark , Kamen, Diane L, Charleston, Majithia, Vikas, Jackson, Venuturupalli, Swamy, McMahon, Maureen, Lim, S Sam, Bhairavarasu, Kalpana, Eisen, Seth , Narain, Sonali , Kamen, Diane L , Trotter, Kimberly , Majithia, Vikas , Lee Ching, Cathy , Ramsey-Goldman, Rosalind , Kim, Alfred H J , McMahon, Maureen , Lim, S Sam , Meara, Alexa Simon , Singh, Jasvinder A , Hearld, Larry R. , Annapureddy, Narender , Venuturupalli, Swamy, Wallace, Daniel J , Ramsey‐Goldman, Rosalind , Kim, Alfred H.J. , Lim, S. Sam , Bhairavarasu, Kalpana, Kalunian, Kenneth , Beasley, Timothy Mark , Kamen, Diane L, Charleston, Majithia, Vikas, Venuturupalli, Swamy, McMahon, Maureen, Lim, S Sam, Bhairavarasu, Kalpana

Mayo Clinic

Rheumatology | April 13, 2025 | Volume: 64 | Issue: 8 | Pages: 4631-4640

10.1093/rheumatology/keaf205 | PMID 40221856 Get It

Abstract Objective The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. Methods We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019–2024 (including the COVID pandemic). We undertook Organizational Readiness to Implement Change Surveys (ORICs) and Team Learning and Psychological Safety Surveys (TLPSSs) at baseline. The primary study outcome objective measure, percent penetration/reach, was defined as the number of patients who viewed the lupus PtDA at the end of the study, divided by the total number of eligible patients (times 100). We used validated clinical personnel surveys to examine the perceived lupus PtDA appropriateness, acceptability, feasibility, success, and permanence, at 4 months, 12 months and 24 months post-PtDA implementation. Results Among the sites, the clinical personnels’ (n = 184) baseline ORIC commitment and efficacy scores (a 0–5 scale, higher = better) ranged from 3.5 to 4.2, and 3.4 to 4.4, respectively; the TLPSS scores (a 0–7 scale, higher = better) were 3.9–5.5 for internal learning, 3.7–5.6 for external learning, and 4.3–5.5 for psychological safety. The penetration (primary outcome) among 15 geographically diverse US rheumatology clinics ranged from 3% to 44%. We found that the total number of providers in the clinic was positively associated with higher penetration. Clinical personnel–perceived lupus PtDA outcomes were optimal at 4 months (all scale scores ranged from 1 to 5, higher = better): (i) appropriateness, 3.43 (s.d. 0.86); (ii) acceptability, 3.53 (s.d. 0.83); (iii) feasibility, 3.44 (s.d. 0.71); (iv) success, 3.41 (s.d. 0.73); and (v) permanence, 3.22 (s.d. 0.74). Conclusion We implemented a lupus PtDA with varied success rates during the COVID pandemic; more providers were associated with higher clinic penetration. Clinical personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24 months. Trial Registration ClinicalTrials.gov, http://clinicaltrials.gov, NCT03735238.
Bilateral External Ear Canal Duplication: A Case Report
Ebbert, Landon E. , Crockett, David J. , Page, Nathan , Ebbert, Joshua , Amoo-Quaye, Grace, Hanson, Nana Andoh Mensah, Appiah–Thompson, Peter , Crockett, David, Page, Nathan C , Crockett, David

Mayo Clinic

Ear, Nose & Throat Journal | April 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/01455613251333233 | PMID 40219830 Get It

Herein described is an eight-year-old female patient presenting with bilateral external ear canal duplication and a history of recurrent postauricular abscesses, otorrhea, and moderate left-sided conductive hearing loss. Previous incision and drainage of the postauricular abscesses yielded little long-term success. Medical history was otherwise unremarkable. Physical examination revealed a cystic mass in the right ear and postauricular fibrosis, likely a result of previous surgical interventions. An audiogram revealed asymmetric hearing function, with mild-to-moderate conductive hearing loss in the left ear contrasting normal hearing in the right ear, while tympanometry confirmed an intact right tympanic membrane but was precluded on the left due to purulent otorrhea. A head CT scan revealed postauricular soft tissue swelling and well-pneumatized mastoid air cells. Both ears were explored intraoperatively via postauricular incisions. Surgical excision included removal of a cyst, cartilaginous remnants, and fibrotic tissue. The patient was followed up to assess for postsurgical complications. The surgical site healed uneventfully; no new symptoms or recurrences of past symptoms of otorrhea, cyst formation, or abscesses had developed within the twelve weeks post-surgery. Although external ear canal duplications are rare, it is imperative that early, accurate diagnoses be made to ensure optimal patient outcomes.
Association of Body Mass Index in Late Life, and Change from Midlife to Late Life, With Incident Dementia in the ARIC Study Participants
Cannon, Ethan , Windham, B. Gwen , Griswold, Michael , Palta, Priya , Knopman, David S. , Sedaghat, Sanaz , Lutsey, Pamela L. , Knopman, David S. , Griswold, Michael , Cannon, Ethan J , Lutsey, Pamela L

Mayo Clinic

Neurology | April 11, 2025 | Volume: 104 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000213534 | PMID 40215425 Get It